Back to top

LACOG | Genitourinary Cancer Group

Board

Dr. Karine Martins da Trindade
Chair
Oncologia D’Or / Instituto D’Or de Pesquisa e Ensino
Fortaleza, Brazil

Dr. Daniel Herchenhorn
Scientific Director
Instituto D’Or de Pesquisa e Ensino
Rio de Janeiro, Brazil

Dr. Manuel Caitano Dias Ferreira Maia
Educational Director
Hospital Mater Dei Porto Dias
Belém, Brazil

Dr. Diogo Augusto Rodrigues da Rosa
Strategic Director
Oncoclínicas
Rio de Janeiro, Brazil

Dr. Daniel Vargas Pivato De Almeida
Co-Executive Director for Brazil
Oncoclínicas Brasília
Brasília, Brazil

Dr. Federico Losco
Co-Executive Director for LATAM
Instituto Alexander Fleming
Buenos Aires, Argentina

Scientific Steering Committee

Brazil
Dr. Mariane Sousa Fontes Dias
CTTB – Centro de Tratamento de Tumores Botafogo
Rio de Janeiro

Dr. Denis Leonardo Fontes Jardim
CPO – Centro Paulista de Oncologia
São Paulo

Dr. Pedro Henrique Isaacsson Velho
HMV – Hospital Moinhos de Vento
Porto Alegre

Dr. Fernando Sabino Marques Monteiro
Hospital Sírio-Libanês DF
Brasília

Dr. Augusto Mota
Clínica AMO – Assistência Multidisciplinar em Oncologia
Salvador

Educational Steering Committee

Brazil
Dr. Fábio Roberto Kater
BP – A Beneficência Portuguesa de São Paulo
São Paulo

Dr. Ana Paula Garcia Cardoso
HIAE – Hospital Israelita Albert Einstein
São Paulo

Dr. Leonardo Atem Gonçalves De Araújo Costa
CRIO – Centro Regional Integrado de Oncologia
Fortaleza

Dr. Fernando Vidigal
Hospital Brasília do Lago Sul
Brasília

Dr. Maikol Kurahash
Cionc – Centro Integrado De Oncologia De Curitiba
Curitiba

LACOG | Genitourinary Cancer Group

Ongoing studies

LACOG 0121 – PET-PSMA | Retrospective analysis of 68Ga-PSMA-PET in patients with prostate cancer: experience from Brazil (LACOG pPR015)

LACOG 0217 – IRONMAN | Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer

LACOG 0218 – Hercules | A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer OPEN FOR RECRUITMENT

LACOG 0519 – PEACE III | A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III

LACOG 0522 – DORA | DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC). OPEN FOR RECRUITMENT

LACOG 0620 – ExBAT | Extreme Bipolar Androgen Therapy with Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (ExBAT trial)

LACOG 1120 – RENAL REGISTRY | Clinicopathological characteristics and outcomes of patients with Renal Cell Carcinoma in Latin America

LACOG 1818 – Prostate Cancer Registry | Survival outcomes in metastatic prostate cancer in the Brazilian population – analysis of individual characteristics and treatment modalities in different national health institutions

LACOG 2018 – Foundation Penile | Molecular characterization of penile cancer in developing countries.